



# Minutes from Extraordinary General Meeting in FluoGuide A/S

Copenhagen, Denmark, 21 June 2021 – FluoGuide A/S, CVR no. 39 29 64 38 (“FluoGuide” or the “Company”) held an extraordinary general meeting on 21 June 2021 at 14:00 (CET) at Ole Maaløes Vej 3, room M4, DK-2200 Copenhagen N, Denmark.

The agenda for the general meeting was as follows:

1. ELECTION OF CHAIRMAN OF THE MEETING
2. ELECTION OF MEMBER TO THE BOARD OF DIRECTORS
3. MISCELLANEOUS

**Following was decided on the extraordinary General Meeting:**

**Re 1: Election of chairman of the meeting**

Henrik Moltke was unanimously elected as the chairman of the general meeting.

**Re 2: Election of member to the board of directors**

The general meeting unanimously decided to elect Mats Thorén as a new member of the Company's board of directors.

**Re 3:**

There was no business to be attended.

The general meeting was closed.

**For further information, please contact:**

Henrik Moltke, CFO

+45 22 44 54 04

hm@fluoguide.com

**Certified Adviser:**

Svensk Kapitalmarknadsgranskning AB

Phone: +46 70 755 95 51

E-mail: ca@skmg.se

**About FluoGuide**

FluoGuide's primary focus is to maximize surgical outcomes in oncology. The Company's lead product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide's products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, the improved precision will improve a patient's chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma. FluoGuide is listed on Nasdaq First North Sweden under the

ticker "FLUO".